- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07593872
XR-Assisted PET/CT Navigation for Cervical Lymph Node Dissection in Lung Cancer (XR-NeckLND)
Application of Extended Reality (XR)-Assisted PET/CT Fusion Navigation in Supraclavicular-to-Cervical Lymph Node Dissection for Lung Cancer
This single-arm, prospective feasibility study evaluates an Extended Reality (XR) headset-based preoperative surgical planning workflow that fuses 18F-FDG PET metabolic hotspots with CT anatomy on the OpVerse platform, in patients with non-small cell lung cancer (NSCLC) and supraclavicular or cervical lymph node metastasis (N3 disease) requiring lymph node dissection. Ten participants will undergo standard preoperative contrast-enhanced CT and whole-body PET. Synapse 3D software is used to segment key anatomic structures (clavicle, sternocleidomastoid, internal jugular vein, subclavian vessels, brachial plexus) and to project PET SUV hotspots onto the high-resolution CT model, yielding a patient-specific digital twin of functional tumor boundaries and at-risk neurovascular structures.
Immediately prior to skin incision, the operating surgeon dons an XR head-mounted display (HoloLens via OpVerse) and registers the digital twin to the patient's neck using stable bony landmarks (clavicular head, sternal notch, mastoid). The surgeon plans the optimal incision and initial dissection trajectory, avoiding superficial veins and projecting the location of deep PET-positive nodes. The XR device is then removed, and the planned cervical or supraclavicular lymph node dissection is performed using standard surgical technique without further intraoperative XR guidance.
The primary endpoint is a composite of safety and feasibility: absence of Grade ≥2 (Clavien-Dindo) phrenic nerve, brachial plexus, chyle leak, Horner syndrome, or major vascular injury through 30 days postoperatively, together with successful XR registration and incision planning. Secondary endpoints include incision planning accuracy, PET hotspot clearance rate, target registration error, operative time, estimated blood loss, and lymph node yield.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Background and Rationale NSCLC with supraclavicular or cervical lymph node metastasis (N3 disease) was historically considered unresectable. With the advance of multimodal therapy, complete lymph node dissection in selected patients has been shown to improve locoregional control. However, the supraclavicular fossa - frequently described as 'Pandora's Box' - is anatomically narrow and dense, with metastatic nodes often abutting the subclavian vessels, internal jugular vein, phrenic nerve, and brachial plexus. Conventional surgery relies heavily on the surgeon's tactile experience and 2D mental reconstruction of preoperative CT, increasing the risk of inadvertent neurovascular injury and incomplete clearance of post-treatment fibrotic versus active disease.
Intervention This study integrates two complementary technologies. (1) Multimodal image fusion using Fujifilm Synapse 3D maps PET SUV hotspots representing biologically active tumor onto a high-resolution CT anatomical model, producing a patient-specific digital twin. The fused model is exported to a static 3D format (OBJ/STL) and imported into the OpVerse XR platform - an offline data-conversion workflow with no real-time API coupling between the two systems, ensuring system stability and software compatibility. (2) Preoperative XR planning: in the operating room after general anesthesia and head/neck positioning, the surgeon wears an XR head-mounted display (HoloLens) and performs surface registration using stable bony landmarks. The 'see-through' overlay enables the surgeon to identify subcutaneous tumor hotspots and superficial venous anatomy, and to mark the optimal skin incision and initial dissection trajectory before any cut is made. The XR headset is then removed; lymph node dissection proceeds using standard sterile technique. Therefore the device functions purely as a preoperative visual aid (Non-Significant Risk), without entry into the sterile operative field.
Lymph node dissection definition En bloc systematic resection of the fibrofatty tissue containing metastatic nodes within the defined cervical or supraclavicular region, to achieve oncologic clearance and provide adequate tissue for pathologic staging and next-generation sequencing.
Statistical analysis All analyses are performed using SPSS. Continuous variables (operative time, blood loss, lymph node count) are summarized as mean ± SD or median; categorical variables (complications, registration success) as frequency and percentage. Successful completion rate of the XR-assisted workflow is reported with 95% confidence intervals. As a single-arm feasibility trial, no formal hypothesis testing is planned.
Preliminary data The investigators have completed a prior pilot trial (REC 202502149RINB, 2025) of XR-assisted lung nodule localization in 20 patients undergoing thoracoscopic sublobar resection, achieving 6-7 mm mean target registration error and 19/20 successful localizations without major complications. Because the supraclavicular region is more rigidly tethered to the bony skeleton and less affected by respiratory motion, registration accuracy in the present study is expected to be ≤5 mm.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Chih-Hsiang Chang
- Numéro de téléphone: 53384 +886-2-2312-3456
- E-mail: changch1986@ntuh.gov.tw
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age 18 to 80 years.
- Confirmed or highly suspected lung cancer with supraclavicular or cervical lymph node metastasis requiring lymph node dissection.
- Willing to undergo preoperative PET/CT imaging.
- Able to provide written informed consent.
Exclusion Criteria:
- Prior high-dose radiation therapy to the neck causing severe distortion of cervical anatomy.
- Inability to undergo imaging studies, or known allergy to iodinated contrast media.
- Vulnerable populations as defined by local IRB regulations (e.g., pregnant women, prisoners, individuals lacking decisional capacity).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Faisabilité de l'appareil
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: XR-Assisted Surgical Planning
Patients undergo XR-assisted preoperative incision planning using the OpVerse platform with HoloLens HMD, overlaying a PET/CT-fused 3D digital twin onto the patient's neck before skin incision.
The XR device is then removed, and standard cervical/supraclavicular lymph node dissection is performed without intraoperative XR guidance.
|
An offline workflow in which patient-specific PET/CT-fused 3D models built in Synapse 3D are exported to OBJ/STL format and rendered via the OpVerse platform on a HoloLens head-mounted display.
The surgeon performs surface registration to bony landmarks of the neck and shoulder for preoperative incision planning.
The device is removed prior to skin incision and is not used during the sterile dissection.
En bloc systematic resection of fibrofatty tissue and metastatic lymph nodes within the cervical or supraclavicular region, performed using standard open surgical technique after XR-assisted incision planning.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Successful Completion of XR-Assisted Preoperative Surgical Planning Workflow
Délai: Intraoperatively, prior to skin incision (Day 0)
|
Proportion of participants in whom the complete XR-assisted preoperative planning workflow is successfully executed, defined as meeting ALL of the following technical criteria:
|
Intraoperatively, prior to skin incision (Day 0)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Procedure-Related Adverse Events
Délai: From surgery through 30 days postoperatively
|
Proportion of participants experiencing Grade ≥2 (Clavien-Dindo classification) adverse events related to the surgical procedure, including phrenic nerve injury, brachial plexus injury, chyle leak, Horner syndrome, or major vascular injury.
|
From surgery through 30 days postoperatively
|
|
Surgeon-Assessed Adequacy of XR-Planned Surgical Incision (3-Point Categorical Scale)
Délai: Intraoperatively, at time of skin incision and during initial dissection (Day 0)
|
Adequacy of the XR-planned skin incision in exposing the targeted lymph nodes, assessed intraoperatively by the operating surgeon using a 3-point categorical scale:
The endpoint is reported as the proportion of cases (out of 10) in each grade. |
Intraoperatively, at time of skin incision and during initial dissection (Day 0)
|
|
PET Hotspot Clearance Rate
Délai: At time of surgery
|
Proportion of preoperatively identified PET-positive lymph nodes (SUV hotspots) that are completely resected, confirmed by review of the operative specimen against preoperative imaging.
|
At time of surgery
|
|
Target Registration Error (TRE)
Délai: At time of surgery
|
Mean spatial offset (millimeters) between virtual model bony landmarks and corresponding patient anatomy after XR surface registration.
|
At time of surgery
|
|
Operative Time
Délai: At time of surgery
|
Total time from skin incision to skin closure (minutes).
|
At time of surgery
|
|
Estimated Intraoperative Blood Loss
Délai: At time of surgery
|
Volume of blood loss recorded during the procedure (milliliters).
|
At time of surgery
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Jin-Shing Chen, National Taiwan University Hospital
Publications et liens utiles
Publications générales
- Sadeghi AH, Mathari SE, Abjigitova D, Maat APWM, Taverne YJHJ, Bogers AJJC, Mahtab EAF. Current and Future Applications of Virtual, Augmented, and Mixed Reality in Cardiothoracic Surgery. Ann Thorac Surg. 2022 Feb;113(2):681-691. doi: 10.1016/j.athoracsur.2020.11.030. Epub 2020 Dec 19.
- Zheng YA, Lee YC, Huang JY, Hsieh HY, Chen YS, Chiang XH, Han PH, Lin MW, Hsu HH, Hung YP, Chen JS. Enhancing three-dimensional anatomical understanding in complex thoracic surgery: a comparative study of OpVerse and Synapse 3D. Eur J Cardiothorac Surg. 2025 Mar 28;67(4):ezaf069. doi: 10.1093/ejcts/ezaf069.
- Ueda K, Tanaka T, Hayashi M, Tanaka N, Li TS, Hamano K. What proportion of lung cancers can be operated by segmentectomy? A computed-tomography-based simulation. Eur J Cardiothorac Surg. 2012 Feb;41(2):341-5. doi: 10.1016/j.ejcts.2011.05.034. Epub 2011 Dec 12.
- Jensen K, Ringsted C, Hansen HJ, Petersen RH, Konge L. Simulation-based training for thoracoscopic lobectomy: a randomized controlled trial: virtual-reality versus black-box simulation. Surg Endosc. 2014 Jun;28(6):1821-9. doi: 10.1007/s00464-013-3392-7. Epub 2014 Jan 18.
- Hu Y, Malthaner RA. The feasibility of three-dimensional displays of the thorax for preoperative planning in the surgical treatment of lung cancer. Eur J Cardiothorac Surg. 2007 Mar;31(3):506-11. doi: 10.1016/j.ejcts.2006.11.054. Epub 2007 Jan 16.
- Bakhuis W, Sadeghi AH, Moes I, Maat APWM, Siregar S, Bogers AJJC, Mahtab EAF. Essential Surgical Plan Modifications After Virtual Reality Planning in 50 Consecutive Segmentectomies. Ann Thorac Surg. 2023 May;115(5):1247-1255. doi: 10.1016/j.athoracsur.2022.08.037. Epub 2022 Sep 6.
- Sato M, Kobayashi M, Kojima F, Tanaka F, Yanagiya M, Kosaka S, Fukai R, Nakajima J. Effect of virtual-assisted lung mapping in acquisition of surgical margins in sublobar lung resection. J Thorac Cardiovasc Surg. 2018 Oct;156(4):1691-1701.e5. doi: 10.1016/j.jtcvs.2018.05.122. Epub 2018 Jul 20.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs par site
- Tumeurs
- Maladies des voies respiratoires
- Maladies pulmonaires
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Processus néoplasiques
- Tumeurs pulmonaires
- Carcinome bronchique
- Tumeurs bronchiques
- Métastase néoplasmique
- Conditions pathologiques, signes et symptômes
- Carcinome pulmonaire non à petites cellules
- Métastase lymphatique
Autres numéros d'identification d'étude
- 202602094DINA
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .